Jeff M. Michalski, MD, MBA, on Medulloblastoma and Radiation Treatment in Pediatric Patients
2020 ASTRO Annual Meeting
Jeff M. Michalski, MD, MBA, of the Washington University School of Medicine, discusses a Children’s Oncology Group study that confirmed data previously reported: Involved-field radiotherapy is noninferior to posterior fossa radiotherapy in patients with average risk-medulloblastoma. However, low-dose craniospinal irradiation is not as effective as standard-dose irradiation in younger children (Abstract 1).
Daniel E. Spratt, MD, of the University of Michigan Rogel Cancer Center, discusses a pooled analysis of two phase III trials showing adjuvant androgen-deprivation therapy (ADT) improves biochemical control and reduces distant metastasis when compared with a neoadjuvant approach, with no difference in late gastrointestinal or genitourinary toxicities. The analysis also showed that delaying radiotherapy to deliver neoadjuvant ADT did not benefit most patients (Abstract 32).
Alphonse G. Taghian, MD, PhD, of Massachusetts General Hospital, reviews the 10-year follow-up of a dose-escalation trial studying accelerated partial-breast irradiation and discusses the optimal dose, adverse effects, and cosmetic outcomes (Abstract 25).
Daniel E. Spratt, MD, of the University of Michigan Rogel Cancer Center, discusses phase III results of the HERO trial, which suggested benefits of the oral medication relugolix: a substantially faster time to castration with longer duration, fewer cardiac events, and a faster return to normal testosterone levels compared with leuroplide (Abstract 35).
Neha Vapiwala, MD, of the University of Pennsylvania, who served as a discussant for LBA1, summarizes her review of this study of patients with prostate cancer who had biochemical recurrence in the post-prostatectomy setting, who were candidates for salvage radiotherapy, and who received either conventional imaging or PET scans to help determine the course of treatment.
Arjun Sahgal, MD, of the Sunnybrook Health Sciences Centre, discusses results of the first phase III trial to suggest that dose escalation with stereotactic body radiotherapy may be superior to conventional palliative radiotherapy in improving pain outcomes for patients with spinal bone metastases (Abstract LBA2).